- Generic name
- Erlotinib
- Strength
- 100 mg
- Dosage form
- Tablet
- Manufactured by
- Synovia Pharma PLC.
Synteva 100 mg Tablet
About Synteva 100 mg Tablet
Synteva 100 mg is a tablet of erlotinib, a targeted cancer therapy used in certain lung cancers. It works by blocking a signalling protein that some cancer cells rely on to grow and divide.
There are 2 brands of Erlotinib listed in Bangladesh. The lowest listed price is Synteva 150 mg Tablet at ৳ 900 per unit.
What is Synteva 100 mg Tablet?
Synteva 100 mg is an oral targeted cancer medicine containing erlotinib. It belongs to a group of drugs that interfere with a specific protein on cancer cells, called the epidermal growth factor receptor, which can drive uncontrolled growth. By blocking signals from this receptor, the medicine aims to slow the growth of tumours that depend on it. It is prescribed only for particular cancers after testing shows the tumour has the relevant receptor changes. Erlotinib is used in some patients with metastatic non-small cell lung cancer, and in some settings together with other cancer treatment. Only a cancer specialist decides whether it suits a person.
Uses of Synteva 100 mg
Synteva 100 mg is used in adults with metastatic non-small cell lung cancer whose tumours have certain epidermal growth factor receptor mutations, as detected by testing. It can be given as first-line treatment, as maintenance treatment for locally advanced or metastatic disease that has not progressed after platinum-based chemotherapy, or in other situations the specialist considers appropriate. It is also used in some pancreatic cancer treatment plans in combination with another medicine. Your cancer doctor decides whether this medicine is suitable and what other treatment it should be combined with.
How to use Synteva 100 mg
Take Synteva 100 mg exactly as your cancer doctor prescribes. The tablet is swallowed whole, usually with water, on an empty stomach. The doctor decides the dose and how long treatment continues, and may adjust or pause it depending on how the cancer responds and on side effects. Do not change the dose or stop on your own. If you miss a dose, ask your doctor or pharmacist what to do rather than taking extra. Tell your treatment team about all other medicines, vitamins and herbal products you use.
Side effects of Synteva 100 mg
Common side effects include rash, diarrhoea, loss of appetite, tiredness, shortness of breath, cough, nausea and vomiting. Some people develop serious problems, including lung inflammation, kidney problems, liver injury, bowel perforation, severe skin blistering or peeling, heart attack or stroke, eye problems and bleeding, especially with warfarin. Seek medical help quickly for new or worsening breathing trouble, severe diarrhoea, yellowing of the skin or eyes, severe skin reactions, chest pain or unusual bleeding. Your team will monitor you and advise what to do.
Safety and precautions
Synteva 100 mg can harm an unborn baby, so pregnancy should be avoided during treatment; tell your doctor if you are pregnant or planning pregnancy. It is not known whether erlotinib passes into breast milk, so breastfeeding decisions should be discussed with your doctor. Before starting, tell your doctor about lung disease, kidney or liver problems, stomach or bowel problems, eye conditions, heart disease, or if you take blood thinners such as warfarin. Your doctor will arrange monitoring and will decide if treatment should be paused or stopped. Do not use it without specialist supervision.
Frequently asked questions
What kind of medicine is Synteva 100 mg and what is it used for?
It is a targeted cancer therapy containing erlotinib, given as a tablet. It is used in certain adults with metastatic non-small cell lung cancer that has specific epidermal growth factor receptor mutations, and in some pancreatic cancer treatment plans. Only a cancer specialist decides if it is appropriate.
Which medicines may interact with Synteva 100 mg?
It can interact with coumarin blood thinners such as warfarin, raising the risk of bleeding and changing blood clotting tests. Some antifungal and antibiotic medicines, and drugs such as rifampicin, can change its blood levels. Tell your doctor and pharmacist about every medicine, supplement and herbal product you take before starting.
What does the generic name erlotinib mean?
Erlotinib is the generic name of the active substance in the tablet. It identifies the medicine itself rather than the brand. It belongs to a class of targeted cancer drugs that block signals from the epidermal growth factor receptor, a protein that can drive tumour growth in some cancers.
How should I store Synteva 100 mg tablets?
Keep the tablets at a temperature not exceeding 30°C in a dry place, protected from light and moisture. Store them out of reach of children and do not use after the expiry date. Ask your pharmacist how to dispose of any unused tablets safely.
Indications
Maintenance treatment of patients with locally advanced or metastatic NSCLC whose ... Read moreFirst-line treatment of patients with metastatic Non-Small Cell Lung cancer (NSCLC) whose tumors have Epidermal Growth Factor Receptor (EGFR) exon 19 deletions or exon 21 substitution mutations as detected.
Maintenance treatment of patients with locally advanced or metastatic NSCLC whose disease has not progressed after four cycles of platinum based first-line chemotherapy.
Treatment of locally advanced or metastatic NSCLC after failure of at least one prior chemotherapy regimen.
First-line treatment of patients with locally advanced, unresectable or metastatic pancreatic cancer, in combination with gemcitabine.
Dosage & Administration
Pancreatic Cancer: The recommended daily dose of Erlotinib for pancreatic cancer is 100 mg taken once daily in combination with gemcitabine. Take Erlotinib on an empty stomach, i.e., at least one hour before or two hours after the ingestion of food. Treatment should continue until disease progression or unacceptable toxicity occurs.
Reduce Erlotinib by 50 mg decrements: If severe reactions occur with concomitant use of strong CYP3A4 inhibitors (such as atazanavir, Clarithromycin, Indinavir, Itraconazole, Ketoconazole, Nefazodone, Nelfinavir, Ritonavir, Saquinavir, Telithromycin, Voriconazole or grapefruit or grapefruit juice] or when using concomitantly with an inhibitor of both CYP3A4 and CYP1A2 (e.g., Ciprofloxacin).
Increase Erlotinib by 50 mg increments as tolerated for: Concomitant use with CYP3A4 inducers, such as rifampin, rifabutin, rifapentine, phenytoin, carbamazepine, phenobarbital, or St. John's Wort. Increase doses by 50 mg increments at 2 week intervals to a maximum of 450 mg. Avoid concomitant use, if possible.
Concurrent cigarette smoking: Increase by 50 mg increments at 2 week intervals to a maximum of 300 mg. Immediately reduce the dose of Erlotinib to the recommended dose (150 mg or 100 mg daily) upon cessation of smoking.
Interaction
CYP3A4 inhibitors: Erlotinib is metabolized predominantly by CYP3A4. Co-treatment with the potent CYP3A4 inhibitor ketoconazole increased Erlotinib AUC by 67%. When Erlotinib was co-administered with Ciprofloxacin, an inhibitor of both CYP3A4 and CYP1A2, the Erlotinib exposure [AUC] and maximum concentration [Cmax] increased by 39% and 17%, respectively.
CYP3A4 inducers: Pre-treatment with the CYP3A4 inducer Rifampicin for 7-11 days prior to Erlotinib decreased Erlotinib AUC by 58% to 80%. Dose modifications are recommended.
Drugs affecting gastric pH: Co-administration of Erlotinib with omeprazole decreased Erlotinib AUC by 46% and co-administration of Erlotinib with Ranitidine 300 mg decreased Erlotinib AUC by 33%.
Side Effects
- Interstitial Lung Disease (ILD)
- Renal Failure
- Hepatotoxicity with or without Hepatic Impairment
- Gastrointestinal Perforation
- Bullous and Exfoliative Skin Disorders
- Myocardial Infarction/Ischemia
- Cerebrovascular Accident
- Microangiopathic Hemolytic Anemia with Thrombocytopenia
- Ocular Disorders
- Hemorrhage in Patients Taking Warfarin
Pregnancy & Lactation
Precautions & Warnings
- Interstitial Lung Disease (ILD): Occurs in 1.1% of patients. Withhold Erlotinib for acute onset of new or progressive unexplained pulmonary symptoms, such as dyspnea, cough and fever. Discontinue Erlotinib if ILD is diagnosed.
- Renal Failure: Monitor renal function and electrolytes, particularly in patients at risk of dehydration. Withhold Erlotinib for severe renal toxicity.
- Hepatotoxicity with or without hepatic impairment including hepatic failure and hepatorenal syndrome: Monitor periodic liver testing. Withhold or discontinue Erlotinib for severe or worsening liver tests.
- Gastrointestinal perforations-discontinue Erlotinib.
- Bullous and exfoliative skin disorders-discontinue Erlotinib.
- Myocardial infarction (Ml)/ischemia: The risk of Ml is increased in patients with pancreatic cancer.
Overdose Effects
Storage Conditions
Alternative brands of Erlotinib
Other brands with the same generic name, cheapest first.
Medicine information is for reference only and is not medical advice. Always follow your doctor's prescription and check with a pharmacist.